drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00313 | DB01619 | 556 | 830 | [
"DDInter1913",
"DDInter1441"
] | Valproic acid | Phenindamine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Moderate | 1 | [
[
[
556,
24,
830
]
],
[
[
556,
24,
537
],
[
537,
40,
830
]
],
[
[
556,
24,
13
],
[
13,
24,
830
]
],
[
[
556,
24,
104
],
[
104,
1,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interact... |
DB00054 | DB00939 | 1,432 | 1,338 | [
"DDInter6",
"DDInter1135"
] | Abciximab | Meclofenamic acid | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
1432,
24,
1338
]
],
[
[
1432,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
1432,
25,
1347
],
[
1347,
24,
1338
]
],
[
[
1432,
64,
1271
],
[
12... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Abciximab may lead to a major life threatening interaction when taken with Clopidogrel... |
DB00480 | DB08904 | 1,668 | 375 | [
"DDInter1035",
"DDInter342"
] | Lenalidomide | Certolizumab pegol | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1668,
25,
375
]
],
[
[
1668,
24,
200
],
[
200,
63,
375
]
],
[
[
1668,
63,
66
],
[
66,
24,
375
]
],
[
[
1668,
25,
671
],
[
671,
2... | [
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[... | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00208 | DB09104 | 1,018 | 286 | [
"DDInter1804",
"DDInter1118"
] | Ticlopidine | Magnesium hydroxide | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
1018,
23,
286
]
],
[
[
1018,
24,
109
],
[
109,
23,
286
]
],
[
[
1018,
23,
1252
],
[
1252,
23,
286
]
],
[
[
1018,
25,
1468
],
[
1468,
... | [
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Digoxin and Di... |
DB00762 | DB06717 | 613 | 875 | [
"DDInter973",
"DDInter778"
] | Irinotecan | Fosaprepitant | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Moderate | 1 | [
[
[
613,
24,
875
]
],
[
[
613,
63,
723
],
[
723,
1,
875
]
],
[
[
613,
21,
29180
],
[
29180,
60,
875
]
],
[
[
613,
24,
466
],
[
466,
... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound)
Irinotecan (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Fosaprepitant (Compound)
Irinotecan may c... |
DB00196 | DB09237 | 600 | 1,586 | [
"DDInter743",
"DDInter1045"
] | Fluconazole | Levamlodipine | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
600,
24,
1586
]
],
[
[
600,
23,
466
],
[
466,
62,
1586
]
],
[
[
600,
24,
578
],
[
578,
23,
1586
]
],
[
[
600,
24,
870
],
[
870,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Levamlodipine
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and T... |
DB00382 | DB01097 | 62 | 1,377 | [
"DDInter1734",
"DDInter1033"
] | Tacrine | Leflunomide | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
62,
25,
1377
]
],
[
[
62,
24,
112
],
[
112,
24,
1377
]
],
[
[
62,
24,
1491
],
[
1491,
64,
1377
]
],
[
[
62,
23,
1001
],
[
1001,
... | [
[
[
"Tacrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Tacrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazol... | Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide
Tacrine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Mido... |
DB01067 | DB01261 | 959 | 170 | [
"DDInter826",
"DDInter1679"
] | Glipizide | Sitagliptin | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
959,
24,
170
]
],
[
[
959,
5,
11640
],
[
11640,
44,
170
]
],
[
[
959,
6,
8374
],
[
8374,
45,
170
]
],
[
[
959,
21,
28921
],
[
28921,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Glipizide",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
"... | Glipizide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Glipizide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caus... |
DB00704 | DB01230 | 267 | 795 | [
"DDInter1263",
"DDInter1416"
] | Naltrexone | Pemoline | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. | In 2005, the Food and Drug Administration (FDA) withdrew approval for pemoline. In March 2005, Abbott Laboratories (Cylert marketer) had discontinued the production of Cylert arguing economic reasons. | Moderate | 1 | [
[
[
267,
24,
795
]
],
[
[
267,
24,
1613
],
[
1613,
63,
795
]
],
[
[
267,
63,
305
],
[
305,
24,
795
]
],
[
[
267,
25,
1510
],
[
1510,
... | [
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pemoline"
]
],
[
[
"Naltrexone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
],... | Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Pemoline
Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB00635 | DB06688 | 1,573 | 1,430 | [
"DDInter1515",
"DDInter1677"
] | Prednisone | Sipuleucel-T | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1573,
24,
1430
]
],
[
[
1573,
1,
175
],
[
175,
24,
1430
]
],
[
[
1573,
25,
676
],
[
676,
63,
1430
]
],
[
[
1573,
24,
1531
],
[
1531,
... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} may cause a... | Prednisone (Compound) resembles Triamcinolone (Compound) and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Prednisone may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could ex... |
DB00370 | DB12332 | 1,251 | 1,619 | [
"DDInter1230",
"DDInter1626"
] | Mirtazapine | Rucaparib | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1251,
24,
1619
]
],
[
[
1251,
25,
222
],
[
222,
23,
1619
]
],
[
[
1251,
23,
112
],
[
112,
23,
1619
]
],
[
[
1251,
24,
1662
],
[
1662,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutram... | Mirtazapine may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Mirtazapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may c... |
DB01097 | DB13873 | 1,377 | 1,534 | [
"DDInter1033",
"DDInter719"
] | Leflunomide | Fenofibric acid | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L128... | Major | 2 | [
[
[
1377,
25,
1534
]
],
[
[
1377,
64,
267
],
[
267,
24,
1534
]
],
[
[
1377,
25,
1613
],
[
1613,
24,
1534
]
],
[
[
1377,
63,
959
],
[
959,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fenofibric acid"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naltrexone"
],
[
"Naltrexone",
... | Leflunomide may lead to a major life threatening interaction when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Fenofibric acid
Leflunomide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta... |
DB00722 | DB00959 | 743 | 1,486 | [
"DDInter1079",
"DDInter1191"
] | Lisinopril | Methylprednisolone | Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldos... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
743,
24,
1486
]
],
[
[
743,
63,
175
],
[
175,
40,
1486
]
],
[
[
743,
24,
167
],
[
167,
1,
1486
]
],
[
[
743,
24,
617
],
[
617,
4... | [
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles ... |
DB00530 | DB08938 | 1,195 | 1,384 | [
"DDInter667",
"DDInter1112"
] | Erlotinib | Magaldrate | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1195,
24,
1384
]
],
[
[
1195,
24,
1220
],
[
1220,
23,
1384
]
],
[
[
1195,
63,
752
],
[
752,
23,
1384
]
],
[
[
1195,
63,
362
],
[
362,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cime... |
DB00448 | DB00673 | 1,215 | 723 | [
"DDInter1022",
"DDInter112"
] | Lansoprazole | Aprepitant | Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective at promoting healing in ulcerative diseases, and treating gastroesophageal reflux ... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
1215,
24,
723
]
],
[
[
1215,
24,
875
],
[
875,
40,
723
]
],
[
[
1215,
6,
7950
],
[
7950,
45,
723
]
],
[
[
1215,
21,
28890
],
[
28890,
... | [
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Lansoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
... | Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Lansoprazole (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Lansoprazole (Compound) causes Myocardial infarction (Si... |
DB06317 | DB11793 | 1,626 | 738 | [
"DDInter630",
"DDInter1297"
] | Elotuzumab | Niraparib | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1626,
24,
738
]
],
[
[
1626,
63,
663
],
[
663,
24,
738
]
],
[
[
1626,
24,
496
],
[
496,
24,
738
]
],
[
[
1626,
24,
1129
],
[
1129,
... | [
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Elotuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
... | Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Elotuzumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccin... |
DB00446 | DB11989 | 597 | 1,434 | [
"DDInter351",
"DDInter183"
] | Chloramphenicol | Benznidazole | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017. It is the first treatment made available in the United States for Chagas disease. | Moderate | 1 | [
[
[
597,
24,
1434
]
],
[
[
597,
24,
788
],
[
788,
24,
1434
]
],
[
[
597,
24,
148
],
[
148,
63,
1434
]
],
[
[
597,
63,
289
],
[
289,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benznidazole"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Benznidazole
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Secni... |
DB01110 | DB06077 | 86 | 879 | [
"DDInter1209",
"DDInter1102"
] | Miconazole | Lumateperone | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Moderate | 1 | [
[
[
86,
24,
879
]
],
[
[
86,
24,
214
],
[
214,
63,
879
]
],
[
[
86,
24,
392
],
[
392,
24,
879
]
],
[
[
86,
63,
1144
],
[
1144,
24,
... | [
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
]
],
[
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone
Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and L... |
DB00078 | DB11003 | 1,172 | 748 | [
"DDInter898",
"DDInter100"
] | Ibritumomab tiuxetan | Anthrax vaccine | Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1172,
24,
748
]
],
[
[
1172,
25,
676
],
[
676,
63,
748
]
],
[
[
1172,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1172,
64,
1057
],
[
1057,
... | [
[
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
... | Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ustekin... |
DB00390 | DB12010 | 1,252 | 214 | [
"DDInter554",
"DDInter785"
] | Digoxin | Fostamatinib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1252,
24,
214
]
],
[
[
1252,
24,
976
],
[
976,
24,
214
]
],
[
[
1252,
25,
1166
],
[
1166,
24,
214
]
],
[
[
1252,
24,
1017
],
[
1017,
... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Digoxin may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a ... |
DB01592 | DB09472 | 1,596 | 1,383 | [
"DDInter975",
"DDInter1693"
] | Iron | Sodium sulfate | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Moderate | 1 | [
[
[
1596,
24,
1383
]
],
[
[
1596,
63,
839
],
[
839,
25,
1383
]
],
[
[
1596,
63,
839
],
[
839,
25,
609
],
[
609,
24,
1383
]
],
[
[
1596,
... | [
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Iron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"... | Iron may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Sodium sulfate
Iron may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may le... |
DB00054 | DB01166 | 1,432 | 477 | [
"DDInter6",
"DDInter379"
] | Abciximab | Cilostazol | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
1432,
24,
477
]
],
[
[
1432,
23,
297
],
[
297,
62,
477
]
],
[
[
1432,
25,
126
],
[
126,
23,
477
]
],
[
[
1432,
24,
109
],
[
109,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Abciximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Abciximab may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Abciximab may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction ... |
DB00242 | DB15233 | 1,064 | 1,650 | [
"DDInter392",
"DDInter142"
] | Cladribine | Avapritinib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Avapritinib, or BLU-285, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors and advanced systemic mastocytosis.[A189339,L40363] It is one of the first medications available for the trea... | Major | 2 | [
[
[
1064,
25,
1650
]
],
[
[
1064,
25,
1101
],
[
1101,
24,
1650
]
],
[
[
1064,
64,
1257
],
[
1257,
24,
1650
]
],
[
[
1064,
24,
869
],
[
869... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} ... | Cladribine may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Cladribine may lead to a major life threatening interaction when taken with Pegfilgrastim and Pegfilgrastim may cause a modera... |
DB08895 | DB15965 | 976 | 1,330 | [
"DDInter1825",
"DDInter1270"
] | Tofacitinib | Naxitamab | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Major | 2 | [
[
[
976,
25,
1330
]
],
[
[
976,
23,
1193
],
[
1193,
23,
1330
]
],
[
[
976,
64,
1532
],
[
1532,
24,
1330
]
],
[
[
976,
25,
1480
],
[
1480,
... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Tofacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gl... | Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Tofacitinib may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may c... |
DB00305 | DB05273 | 377 | 507 | [
"DDInter1232",
"DDInter1638"
] | Mitomycin | Samarium (153Sm) lexidronam | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Major | 2 | [
[
[
377,
25,
507
]
],
[
[
377,
24,
248
],
[
248,
24,
507
]
],
[
[
377,
24,
270
],
[
270,
63,
507
]
],
[
[
377,
25,
970
],
[
970,
25,... | [
[
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
... | Mitomycin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Mitomycin may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00502 | DB11186 | 1,300 | 1,609 | [
"DDInter853",
"DDInter1427"
] | Haloperidol | Pentoxyverine | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1300,
24,
1609
]
],
[
[
1300,
24,
104
],
[
104,
24,
1609
]
],
[
[
1300,
63,
999
],
[
999,
24,
1609
]
],
[
[
1300,
40,
78
],
[
78,
... | [
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Haloperidol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Haloperidol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylpera... |
DB00188 | DB14443 | 168 | 987 | [
"DDInter222",
"DDInter1931"
] | Bortezomib | Vibrio cholerae CVD 103-HgR strain live antigen | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
168,
24,
987
]
],
[
[
168,
24,
1480
],
[
1480,
24,
987
]
],
[
[
168,
23,
1220
],
[
1220,
24,
987
]
],
[
[
168,
63,
305
],
[
305,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Bortezomib may cause a minor interaction that can limit clinical effects when t... |
DB00653 | DB01285 | 544 | 708 | [
"DDInter1120",
"DDInter445"
] | Magnesium sulfate | Corticotropin | A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
544,
24,
708
]
],
[
[
544,
24,
1436
],
[
1436,
63,
708
]
],
[
[
544,
63,
355
],
[
355,
24,
708
]
],
[
[
544,
24,
336
],
[
336,
2... | [
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Magnesium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"... | Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Patiromer and Patiromer may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lactul... |
DB05015 | DB14730 | 1,077 | 1,412 | [
"DDInter174",
"DDInter264"
] | Belinostat | Calaspargase pegol | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1077,
24,
1412
]
],
[
[
1077,
24,
850
],
[
850,
24,
1412
]
],
[
[
1077,
63,
482
],
[
482,
24,
1412
]
],
[
[
1077,
64,
581
],
[
581,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Belinostat may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00376 | DB00835 | 1,105 | 100 | [
"DDInter1870",
"DDInter245"
] | Trihexyphenidyl | Brompheniramine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
1105,
24,
100
]
],
[
[
1105,
24,
832
],
[
832,
24,
100
]
],
[
[
1105,
24,
649
],
[
649,
63,
100
]
],
[
[
1105,
63,
1594
],
[
1594,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennami... | Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00813 | DB01233 | 704 | 1,311 | [
"DDInter722",
"DDInter1197"
] | Fentanyl | Metoclopramide | Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia.[Label,L6598,L6601,L6604,L6607,L922,L6610,L6613] Fentanyl is related to other opioids like [morphine] and... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
704,
24,
1311
]
],
[
[
704,
10,
11562
],
[
11562,
49,
1311
]
],
[
[
704,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
704,
24,
1383
],
[
13... | [
[
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Fentanyl",
"{u} (Compound) palliates {v} (Disease)",
"prostate cancer"
],
[
"prostate cancer",
"{u} (Disease) ... | Fentanyl (Compound) palliates prostate cancer (Disease) and prostate cancer (Disease) is palliated by Metoclopramide (Compound)
Fentanyl (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Fentanyl may cause a moderate interaction that could exacerbate diseases... |
DB01403 | DB11186 | 9 | 1,609 | [
"DDInter1175",
"DDInter1427"
] | Methotrimeprazine | Pentoxyverine | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
9,
24,
1609
]
],
[
[
9,
1,
508
],
[
508,
24,
1609
]
],
[
[
9,
64,
506
],
[
506,
24,
1609
]
],
[
[
9,
63,
662
],
[
662,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Methotrimeprazine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may ... | Methotrimeprazine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Methotrimeprazine may lead to a major life threatening interaction when taken with Dextromethorphan and Dextromethorphan may cause a moderate interactio... |
DB06822 | DB12500 | 802 | 283 | [
"DDInter1812",
"DDInter714"
] | Tinzaparin | Fedratinib | Tinzaparin is a low molecular weight heparin (LMWH), produced by enzymatic depolymerization of unfractionated heparin from porcine intestinal mucosa. It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons. Tinzaparin is composed of molecules with and without a special site for h... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
802,
25,
283
]
],
[
[
802,
64,
885
],
[
885,
24,
283
]
],
[
[
802,
63,
529
],
[
529,
24,
283
]
],
[
[
802,
25,
1618
],
[
1618,
2... | [
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Tinzaparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{... | Tinzaparin may lead to a major life threatening interaction when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Tinzaparin may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine and Fluvoxamine may ... |
DB00092 | DB06176 | 58 | 1,342 | [
"DDInter40",
"DDInter1616"
] | Alefacept | Romidepsin | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
58,
24,
1342
]
],
[
[
58,
24,
336
],
[
336,
24,
1342
]
],
[
[
58,
24,
1491
],
[
1491,
63,
1342
]
],
[
[
58,
23,
1461
],
[
1461,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nifedipine"
],
[
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midosta... |
DB08901 | DB11760 | 1,468 | 119 | [
"DDInter1492",
"DDInter1742"
] | Ponatinib | Talazoparib | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1468,
24,
119
]
],
[
[
1468,
63,
66
],
[
66,
24,
119
]
],
[
[
1468,
64,
441
],
[
441,
24,
119
]
],
[
[
1468,
24,
1129
],
[
1129,
... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ponatinib may lead to a major life threatening interaction when taken with Delavirdine and Delavirdine may cause... |
DB01229 | DB14783 | 973 | 287 | [
"DDInter1378",
"DDInter574"
] | Paclitaxel (protein-bound) | Diroximel fumarate | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
973,
24,
287
]
],
[
[
973,
63,
1101
],
[
1101,
24,
287
]
],
[
[
973,
24,
384
],
[
384,
24,
287
]
],
[
[
973,
64,
770
],
[
770,
2... | [
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fum... |
DB01611 | DB06595 | 1,487 | 1,491 | [
"DDInter893",
"DDInter1214"
] | Hydroxychloroquine | Midostaurin | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
1487,
25,
1491
]
],
[
[
1487,
63,
112
],
[
112,
23,
1491
]
],
[
[
1487,
62,
1247
],
[
1247,
23,
1491
]
],
[
[
1487,
64,
888
],
[
888,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Su... |
DB00425 | DB00673 | 558 | 723 | [
"DDInter1970",
"DDInter112"
] | Zolpidem | Aprepitant | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
558,
24,
723
]
],
[
[
558,
6,
7950
],
[
7950,
45,
723
]
],
[
[
558,
21,
28890
],
[
28890,
60,
723
]
],
[
[
558,
24,
222
],
[
222,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
... | Zolpidem (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Aprepitant (Compound)
Zolpidem (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Aprepitant (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB00264 | DB05812 | 88 | 1,374 | [
"DDInter1200",
"DDInter8"
] | Metoprolol | Abiraterone | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succi... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
88,
24,
1374
]
],
[
[
88,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
88,
21,
28809
],
[
28809,
60,
1374
]
],
[
[
88,
24,
760
],
[
760,
... | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Metoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Metoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Metoprolol (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Abiraterone (Compound)
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Co... |
DB00220 | DB00889 | 798 | 1,133 | [
"DDInter1276",
"DDInter840"
] | Nelfinavir | Granisetron | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
798,
24,
1133
]
],
[
[
798,
6,
8374
],
[
8374,
45,
1133
]
],
[
[
798,
7,
8386
],
[
8386,
57,
1133
]
],
[
[
798,
21,
28851
],
[
28851,
... | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Nelfinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nelfinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Granisetron (Compound)
Nelfinavir (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Granisetron (Compound)
Nelfinavir (Compound) causes Hepatic enzyme increased (Side Effect) and Hepatic enzyme increased (Side Effect) is ca... |
DB00514 | DB01233 | 506 | 1,311 | [
"DDInter527",
"DDInter1197"
] | Dextromethorphan | Metoclopramide | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
506,
24,
1311
]
],
[
[
506,
6,
12523
],
[
12523,
45,
1311
]
],
[
[
506,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
506,
24,
1020
],
[
102... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Dextromethorphan",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by ... | Dextromethorphan (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoclopramide (Compound)
Dextromethorphan (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when ta... |
DB00366 | DB00647 | 1,594 | 675 | [
"DDInter600",
"DDInter528"
] | Doxylamine | Dextropropoxyphene | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Major | 2 | [
[
[
1594,
36,
675
]
],
[
[
1594,
40,
888
],
[
888,
64,
675
]
],
[
[
1594,
74,
494
],
[
494,
1,
675
]
],
[
[
1594,
24,
1511
],
[
1511,
... | [
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxif... | Doxylamine (Compound) resembles Dextropropoxyphene (Compound) and
Doxylamine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may lead to a major life threatening interaction when taken with Dextropropoxyphene
Doxylamine (Compound) resembles Disopyramide (Compound) and Doxylamine may cause a moderate interaction... |
DB00222 | DB00774 | 245 | 1,577 | [
"DDInter825",
"DDInter889"
] | Glimepiride | Hydroflumethiazide | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Moderate | 1 | [
[
[
245,
24,
1577
]
],
[
[
245,
24,
359
],
[
359,
40,
1577
]
],
[
[
245,
24,
504
],
[
504,
1,
1577
]
],
[
[
245,
21,
29455
],
[
29455,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazide"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) resembles Hydroflumethiazide (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compou... |
DB00372 | DB00373 | 999 | 461 | [
"DDInter1793",
"DDInter1809"
] | Thiethylperazine | Timolol | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Moderate | 1 | [
[
[
999,
24,
461
]
],
[
[
999,
23,
1283
],
[
1283,
62,
461
]
],
[
[
999,
62,
417
],
[
417,
23,
461
]
],
[
[
999,
24,
1450
],
[
1450,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
]
],
[
[
"Thiethylperazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
... | Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a minor interaction that can limit clinical effects when taken with Timolol
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfa... |
DB00414 | DB00968 | 590 | 1,551 | [
"DDInter16",
"DDInter1185"
] | Acetohexamide | Methyldopa | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Minor | 0 | [
[
[
590,
23,
1551
]
],
[
[
590,
24,
817
],
[
817,
40,
1551
]
],
[
[
590,
24,
874
],
[
874,
24,
1551
]
],
[
[
590,
24,
1264
],
[
1264,
... | [
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methyldopa"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dopamine"
],
[
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Dopamine and Dopamine (Compound) resembles Methyldopa (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that c... |
DB00348 | DB00599 | 254 | 682 | [
"DDInter1300",
"DDInter1795"
] | Nitisinone | Thiopental | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration. It is also used for hypnosis and for the control of convulsive states. It has been used in neurosurgical patients to reduce increased intracranial pressure. It does no... | Moderate | 1 | [
[
[
254,
24,
682
]
],
[
[
254,
63,
1023
],
[
1023,
1,
682
]
],
[
[
254,
24,
536
],
[
536,
1,
682
]
],
[
[
254,
24,
752
],
[
752,
23,... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Thiopental (Compound)
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital and Secobarbital (Compound) resembles Thiopental (... |
DB00620 | DB06819 | 175 | 754 | [
"DDInter1855",
"DDInter1452"
] | Triamcinolone | Phenylbutyric acid | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Phenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone. It is used to treat genetic metabolic syndromes, neuropathies, and ur... | Moderate | 1 | [
[
[
175,
24,
754
]
],
[
[
175,
40,
891
],
[
891,
24,
754
]
],
[
[
175,
63,
1236
],
[
1236,
24,
754
]
],
[
[
175,
24,
697
],
[
697,
2... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylbutyric acid"
]
],
[
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} m... | Triamcinolone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutyric acid
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Carbamazepine and Carbamazepine may cause a moderat... |
DB00015 | DB01166 | 582 | 477 | [
"DDInter1585",
"DDInter379"
] | Reteplase | Cilostazol | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids p... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Moderate | 1 | [
[
[
582,
24,
477
]
],
[
[
582,
23,
297
],
[
297,
62,
477
]
],
[
[
582,
25,
126
],
[
126,
23,
477
]
],
[
[
582,
24,
109
],
[
109,
24,... | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Reteplase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clove"
],
[
"Clov... | Reteplase may cause a minor interaction that can limit clinical effects when taken with Clove and Clove may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Reteplase may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction ... |
DB06715 | DB13074 | 239 | 877 | [
"DDInter1500",
"DDInter1110"
] | Potassium Iodide | Macimorelin | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Moderate | 1 | [
[
[
239,
24,
877
]
],
[
[
239,
63,
1171
],
[
1171,
24,
877
]
],
[
[
239,
24,
116
],
[
116,
24,
877
]
],
[
[
239,
24,
1399
],
[
1399,
... | [
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
... | Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Meloxicam and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-1... |
DB00834 | DB14568 | 932 | 982 | [
"DDInter1215",
"DDInter1000"
] | Mifepristone | Ivosidenib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
932,
25,
982
]
],
[
[
932,
23,
112
],
[
112,
23,
982
]
],
[
[
932,
63,
168
],
[
168,
23,
982
]
],
[
[
932,
62,
1101
],
[
1101,
2... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and ... |
DB00744 | DB09122 | 1,288 | 1,613 | [
"DDInter1962",
"DDInter1409"
] | Zileuton | Peginterferon beta-1a | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1288,
24,
1613
]
],
[
[
1288,
63,
267
],
[
267,
24,
1613
]
],
[
[
1288,
24,
351
],
[
351,
63,
1613
]
],
[
[
1288,
24,
478
],
[
478,
... | [
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Zileuton",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
... | Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Zileuton may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and... |
DB00213 | DB01583 | 837 | 624 | [
"DDInter1388",
"DDInter1075"
] | Pantoprazole | Liotrix | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Liotrix is a synthetically derived thyroid hormone replacement preparation. It consists of levothyroxine sodium (thyroxine, T4) and liothyronine sodium (triiodothyronine, T3) in a 4 to 1 ratio by weight. Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal s... | Moderate | 1 | [
[
[
837,
24,
624
]
],
[
[
837,
24,
1152
],
[
1152,
1,
624
]
],
[
[
837,
24,
542
],
[
542,
40,
624
]
],
[
[
837,
6,
15333
],
[
15333,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liotrix"
]
],
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[... | Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Liotrix (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Levothyroxine and Levothyroxine (Compound) resembles Liotrix (Co... |
DB00500 | DB00635 | 24 | 1,573 | [
"DDInter1831",
"DDInter1515"
] | Tolmetin | Prednisone | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Moderate | 1 | [
[
[
24,
24,
1573
]
],
[
[
24,
24,
175
],
[
175,
40,
1573
]
],
[
[
24,
63,
251
],
[
251,
1,
1573
]
],
[
[
24,
24,
167
],
[
167,
1,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Prednisone (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Prednisone (Co... |
DB08865 | DB14575 | 1,593 | 733 | [
"DDInter448",
"DDInter674"
] | Crizotinib | Eslicarbazepine | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Eslicarbazepine is an anti-epileptic medication available commercially as [eslicarbazepine acetate]. | Moderate | 1 | [
[
[
1593,
24,
733
]
],
[
[
1593,
63,
1101
],
[
1101,
23,
733
]
],
[
[
1593,
64,
1264
],
[
1264,
24,
733
]
],
[
[
1593,
25,
1135
],
[
1135,... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eslicarbazepine"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
... | Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Eslicarbazepine
Crizotinib may lead to a major life threatening interaction when taken with Doxepin and Doxepin may cause a m... |
DB06603 | DB11952 | 39 | 800 | [
"DDInter1387",
"DDInter612"
] | Panobinostat | Duvelisib | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
39,
24,
800
]
],
[
[
39,
63,
663
],
[
663,
24,
800
]
],
[
[
39,
24,
270
],
[
270,
63,
800
]
],
[
[
39,
64,
11
],
[
11,
24,
... | [
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Panobinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
... | Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Panobinostat may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab an... |
DB00468 | DB01339 | 1,424 | 728 | [
"DDInter1557",
"DDInter1922"
] | Quinine | Vecuronium | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide ad... | Moderate | 1 | [
[
[
1424,
24,
728
]
],
[
[
1424,
24,
1610
],
[
1610,
1,
728
]
],
[
[
1424,
24,
1579
],
[
1579,
40,
728
]
],
[
[
1424,
6,
4973
],
[
4973,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
],
[
"R... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Rocuronium and Rocuronium (Compound) resembles Vecuronium (Compound)
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Pancuronium and Pancuronium (Compound) resembles Vecuronium (Compound)
Quin... |
DB00834 | DB09078 | 932 | 1,228 | [
"DDInter1215",
"DDInter1036"
] | Mifepristone | Lenvatinib | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Major | 2 | [
[
[
932,
25,
1228
]
],
[
[
932,
23,
112
],
[
112,
23,
1228
]
],
[
[
932,
25,
609
],
[
609,
24,
1228
]
],
[
[
932,
24,
770
],
[
770,
... | [
[
[
"Mifepristone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenvatinib"
]
],
[
[
"Mifepristone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Mifepristone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromy... |
DB00281 | DB00877 | 608 | 629 | [
"DDInter1066",
"DDInter1678"
] | Lidocaine | Sirolimus | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Moderate | 1 | [
[
[
608,
24,
629
]
],
[
[
608,
6,
4973
],
[
4973,
45,
629
]
],
[
[
608,
18,
15501
],
[
15501,
57,
629
]
],
[
[
608,
21,
29276
],
[
29276,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Lidocaine (Compound) downregulates CCDC86 (Gene) and CCDC86 (Gene) is downregulated by Sirolimus (Compound)
Lidocaine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Sirolimus (Compound)
Lido... |
DB01069 | DB01192 | 401 | 560 | [
"DDInter1533",
"DDInter1372"
] | Promethazine | Oxymorphone | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). O... | Moderate | 1 | [
[
[
401,
24,
560
]
],
[
[
401,
63,
828
],
[
828,
1,
560
]
],
[
[
401,
6,
12523
],
[
12523,
45,
560
]
],
[
[
401,
21,
28817
],
[
28817,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxymorphone"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Oxymorphone (Compound)
Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Oxymorphone (Compound)
Promethazine (Compound) causes Vision blurred (Side Effect) an... |
DB00682 | DB06701 | 126 | 1,177 | [
"DDInter1951",
"DDInter521"
] | Warfarin | Dexmethylphenidate | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Dexmethylphenidate is the dextrorotary form of methylphenidate introduced in 2002. It is a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant. It is used for treatment of Attention Deficit Hyperactivity Disorder (ADHD)[Label,A177181]. The d-isomer is thought to have greater effect with fewer s... | Minor | 0 | [
[
[
126,
23,
1177
]
],
[
[
126,
62,
895
],
[
895,
1,
1177
]
],
[
[
126,
24,
1264
],
[
1264,
24,
1177
]
],
[
[
126,
23,
1053
],
[
1053,
... | [
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexmethylphenidate"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylphenidate"
],
... | Warfarin may cause a minor interaction that can limit clinical effects when taken with Methylphenidate and Methylphenidate (Compound) resembles Dexmethylphenidate (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that... |
DB00694 | DB11730 | 51 | 351 | [
"DDInter485",
"DDInter1588"
] | Daunorubicin | Ribociclib | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
51,
25,
351
]
],
[
[
51,
24,
466
],
[
466,
62,
351
]
],
[
[
51,
23,
1247
],
[
1247,
23,
351
]
],
[
[
51,
24,
479
],
[
479,
23,
... | [
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Daro... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Daunorubicin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole ... |
DB00468 | DB00728 | 1,424 | 1,610 | [
"DDInter1557",
"DDInter1612"
] | Quinine | Rocuronium | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechan... | Moderate | 1 | [
[
[
1424,
24,
1610
]
],
[
[
1424,
24,
728
],
[
728,
40,
1610
]
],
[
[
1424,
6,
6648
],
[
6648,
45,
1610
]
],
[
[
1424,
21,
29118
],
[
2911... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rocuronium"
]
],
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vecuronium"
],
[
"V... | Quinine may cause a moderate interaction that could exacerbate diseases when taken with Vecuronium and Vecuronium (Compound) resembles Rocuronium (Compound)
Quinine (Compound) binds SLCO1A2 (Gene) and SLCO1A2 (Gene) is bound by Rocuronium (Compound)
Quinine (Compound) causes Tachycardia (Side Effect) and Tachycardia (S... |
DB06448 | DB06595 | 171 | 1,491 | [
"DDInter1087",
"DDInter1214"
] | Lonafarnib | Midostaurin | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Major | 2 | [
[
[
171,
25,
1491
]
],
[
[
171,
25,
1135
],
[
1135,
62,
1491
]
],
[
[
171,
63,
112
],
[
112,
23,
1491
]
],
[
[
171,
63,
761
],
[
761,
... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
]
],
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} ma... | Lonafarnib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Midostaurin
Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cau... |
DB06772 | DB10989 | 310 | 496 | [
"DDInter259",
"DDInter858"
] | Cabazitaxel | Hepatitis A Vaccine | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infectio... | Moderate | 1 | [
[
[
310,
24,
496
]
],
[
[
310,
63,
4
],
[
4,
24,
496
]
],
[
[
310,
24,
850
],
[
850,
24,
496
]
],
[
[
310,
24,
738
],
[
738,
63,
... | [
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepe... | Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Cabazitaxel may cause a moderate interaction that could exacerbate disea... |
DB00425 | DB00835 | 558 | 100 | [
"DDInter1970",
"DDInter245"
] | Zolpidem | Brompheniramine | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
558,
24,
100
]
],
[
[
558,
24,
832
],
[
832,
24,
100
]
],
[
[
558,
63,
128
],
[
128,
24,
100
]
],
[
[
558,
24,
649
],
[
649,
63,... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
],
... | Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheni... |
DB00674 | DB01041 | 1,516 | 770 | [
"DDInter802",
"DDInter1789"
] | Galantamine | Thalidomide | Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sour... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1516,
24,
770
]
],
[
[
1516,
21,
29425
],
[
29425,
60,
770
]
],
[
[
1516,
24,
609
],
[
609,
63,
770
]
],
[
[
1516,
63,
1557
],
[
1557,... | [
[
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Galantamine",
"{u} (Compound) causes {v} (Side Effect)",
"Myocardial ischaemia"
],
[
"Myocardial ischaemia",
"... | Galantamine (Compound) causes Myocardial ischaemia (Side Effect) and Myocardial ischaemia (Side Effect) is caused by Thalidomide (Compound)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate... |
DB00067 | DB12245 | 317 | 823 | [
"DDInter1921",
"DDInter1863"
] | Vasopressin | Triclabendazole | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
317,
24,
823
]
],
[
[
317,
23,
112
],
[
112,
23,
823
]
],
[
[
317,
24,
1010
],
[
1010,
24,
823
]
],
[
[
317,
24,
1619
],
[
1619,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine a... |
DB00446 | DB01042 | 597 | 1,307 | [
"DDInter351",
"DDInter1144"
] | Chloramphenicol | Melphalan | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
597,
24,
1307
]
],
[
[
597,
24,
1191
],
[
1191,
1,
1307
]
],
[
[
597,
21,
29232
],
[
29232,
60,
1307
]
],
[
[
597,
63,
168
],
[
168,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
],
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Melphalan (Compound)
Chloramphenicol (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Melphalan (Compound)
Chloramphenicol may cause a moderate int... |
DB00860 | DB00963 | 891 | 1,263 | [
"DDInter1513",
"DDInter241"
] | Prednisolone | Bromfenac | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool f... | Moderate | 1 | [
[
[
891,
24,
1263
]
],
[
[
891,
24,
935
],
[
935,
40,
1263
]
],
[
[
891,
63,
831
],
[
831,
40,
1263
]
],
[
[
891,
63,
1512
],
[
1512,
... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromfenac"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
],
[... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ketoprofen and Ketoprofen (Compound) resembles Bromfenac (Compound)
Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Bromfenac (Comp... |
DB00372 | DB00692 | 999 | 274 | [
"DDInter1793",
"DDInter1448"
] | Thiethylperazine | Phentolamine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Moderate | 1 | [
[
[
999,
24,
274
]
],
[
[
999,
24,
1296
],
[
1296,
62,
274
]
],
[
[
999,
63,
1179
],
[
1179,
23,
274
]
],
[
[
999,
63,
695
],
[
695,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin deglu... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a minor interaction that can limit clinical effects when taken with Phentolamine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB01278 | DB12015 | 1,021 | 1,033 | [
"DDInter1506",
"DDInter53"
] | Pramlintide | Alpelisib | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1021,
24,
1033
]
],
[
[
1021,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
1021,
63,
1144
],
[
1144,
24,
1033
]
],
[
[
1021,
24,
1654
],
[
16... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Nategl... |
DB00108 | DB00601 | 1,066 | 453 | [
"DDInter1268",
"DDInter1073"
] | Natalizumab | Linezolid | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Major | 2 | [
[
[
1066,
25,
453
]
],
[
[
1066,
25,
770
],
[
770,
63,
453
]
],
[
[
1066,
24,
1430
],
[
1430,
63,
453
]
],
[
[
1066,
25,
168
],
[
168,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Linezolid"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u... | Natalizumab may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Linezolid
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may... |
DB08816 | DB09054 | 578 | 384 | [
"DDInter1802",
"DDInter905"
] | Ticagrelor | Idelalisib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Major | 2 | [
[
[
578,
25,
384
]
],
[
[
578,
63,
222
],
[
222,
23,
384
]
],
[
[
578,
24,
555
],
[
555,
23,
384
]
],
[
[
578,
23,
907
],
[
907,
62,... | [
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutrami... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupi... |
DB00334 | DB01064 | 867 | 1,148 | [
"DDInter1326",
"DDInter987"
] | Olanzapine | Isoprenaline | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Moderate | 1 | [
[
[
867,
24,
1148
]
],
[
[
867,
24,
480
],
[
480,
24,
1148
]
],
[
[
867,
7,
5178
],
[
5178,
46,
1148
]
],
[
[
867,
18,
6929
],
[
6929,
... | [
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Olanzapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
... | Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Olanzapine (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is upregulated by Isoprenaline (Compound)
Olanza... |
DB00976 | DB01254 | 1,056 | 1,213 | [
"DDInter1758",
"DDInter484"
] | Telithromycin | Dasatinib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
1056,
25,
1213
]
],
[
[
1056,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
1056,
21,
28956
],
[
28956,
60,
1213
]
],
[
[
1056,
62,
112
],
[
11... | [
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Telithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Da... | Telithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Telithromycin (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Dasatinib (Compound)
Telithromycin may cause a minor interaction that can limit clinical effects when taken with Metronid... |
DB00559 | DB08901 | 152 | 1,468 | [
"DDInter223",
"DDInter1492"
] | Bosentan | Ponatinib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
152,
24,
1468
]
],
[
[
152,
24,
478
],
[
478,
24,
1468
]
],
[
[
152,
6,
10083
],
[
10083,
45,
1468
]
],
[
[
152,
18,
5795
],
[
5795,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"N... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Bosentan (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound)
Bosentan (Compound) downre... |
DB00014 | DB00738 | 521 | 485 | [
"DDInter839",
"DDInter1420"
] | Goserelin | Pentamidine | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medi... | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Moderate | 1 | [
[
[
521,
24,
485
]
],
[
[
521,
21,
28981
],
[
28981,
60,
485
]
],
[
[
521,
23,
1247
],
[
1247,
62,
485
]
],
[
[
521,
24,
971
],
[
971,
... | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Renal impairment"
],
[
"Renal impairment",
"{u} (Side Ef... | Goserelin (Compound) causes Renal impairment (Side Effect) and Renal impairment (Side Effect) is caused by Pentamidine (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects wh... |
DB00860 | DB01390 | 891 | 1,117 | [
"DDInter1513",
"DDInter1683"
] | Prednisolone | Sodium bicarbonate | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
891,
23,
1117
]
],
[
[
891,
21,
28778
],
[
28778,
60,
1117
]
],
[
[
891,
40,
1220
],
[
1220,
23,
1117
]
],
[
[
891,
62,
1018
],
[
1018... | [
[
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Prednisolone",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
... | Prednisolone (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Sodium bicarbonate (Compound)
Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Pr... |
DB00836 | DB11978 | 543 | 124 | [
"DDInter1088",
"DDInter822"
] | Loperamide | Glasdegib | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
543,
24,
124
]
],
[
[
543,
24,
112
],
[
112,
23,
124
]
],
[
[
543,
24,
1079
],
[
1079,
24,
124
]
],
[
[
543,
63,
475
],
[
475,
2... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Tel... |
DB03904 | DB14509 | 1,574 | 1,399 | [
"DDInter1903",
"DDInter1081"
] | Urea | Lithium carbonate | A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Minor | 0 | [
[
[
1574,
23,
1399
]
],
[
[
1574,
24,
1344
],
[
1344,
24,
1399
]
],
[
[
1574,
63,
123
],
[
123,
24,
1399
]
],
[
[
1574,
24,
1527
],
[
1527... | [
[
[
"Urea",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Urea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Urea may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Urea may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenat... |
DB00907 | DB01168 | 290 | 1,053 | [
"DDInter427",
"DDInter1526"
] | Cocaine (topical) | Procarbazine | Cocaine can cause developmental toxicity and female reproductive toxicity according to an independent committee of scientific and health experts. | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Major | 2 | [
[
[
290,
25,
1053
]
],
[
[
290,
21,
28975
],
[
28975,
60,
1053
]
],
[
[
290,
63,
839
],
[
839,
23,
1053
]
],
[
[
290,
25,
480
],
[
480,
... | [
[
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
]
],
[
[
"Cocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
... | Cocaine may lead to a major life threatening interaction when taken with Procarbazine
Cocaine (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Procarbazine (Compound)
Cocaine may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may... |
DB00532 | DB11767 | 208 | 1,583 | [
"DDInter1152",
"DDInter1643"
] | Mephenytoin | Sarilumab | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
208,
24,
1583
]
],
[
[
208,
24,
267
],
[
267,
24,
1583
]
],
[
[
208,
63,
482
],
[
482,
24,
1583
]
],
[
[
208,
24,
270
],
[
270,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tiogu... |
DB01234 | DB11714 | 1,220 | 1,316 | [
"DDInter513",
"DDInter610"
] | Dexamethasone | Durvalumab | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Moderate | 1 | [
[
[
1220,
24,
1316
]
],
[
[
1220,
62,
1461
],
[
1461,
23,
1316
]
],
[
[
1220,
23,
1114
],
[
1114,
23,
1316
]
],
[
[
1220,
40,
167
],
[
167... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
]
],
[
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[... | Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Durvalumab
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc s... |
DB00745 | DB11581 | 307 | 1,456 | [
"DDInter1236",
"DDInter1926"
] | Modafinil | Venetoclax | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
307,
25,
1456
]
],
[
[
307,
23,
1135
],
[
1135,
23,
1456
]
],
[
[
307,
25,
1476
],
[
1476,
63,
1456
]
],
[
[
307,
23,
86
],
[
86,
... | [
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Modafinil may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a modera... |
DB01069 | DB11160 | 401 | 337 | [
"DDInter1533",
"DDInter1459"
] | Promethazine | Phenyltoloxamine | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Phenyltoloxamine is an antihistamine drug with sedative and analgesic effects. It is a H1 receptor blocker and a member of the ethanolamine class of antihistaminergic drugs. It is available in combination products that also contain other analgesics and antitussives such as acetaminophen. Phenyltoloxamine citrate is the... | Moderate | 1 | [
[
[
401,
24,
337
]
],
[
[
401,
23,
771
],
[
771,
62,
337
]
],
[
[
401,
24,
820
],
[
820,
24,
337
]
],
[
[
401,
63,
999
],
[
999,
24,... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyltoloxamine"
]
],
[
[
"Promethazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
... | Promethazine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyltoloxamine
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazi... |
DB00018 | DB00531 | 199 | 450 | [
"DDInter945",
"DDInter456"
] | Interferon alfa-n3 | Cyclophosphamide | Purified, natural (n is for natural) human interferon alpha proteins (consists of 3 forms or polymorphisms including 2a, 2b and 2c). 166 residues, some are glycosylated (MW range from 16 kD to 27 kD). | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Minor | 0 | [
[
[
199,
23,
450
]
],
[
[
199,
24,
270
],
[
270,
63,
450
]
],
[
[
199,
25,
1648
],
[
1648,
24,
450
]
],
[
[
199,
25,
593
],
[
593,
6... | [
[
[
"Interferon alfa-n3",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
]
],
[
[
"Interferon alfa-n3",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocreliz... | Interferon alfa-n3 may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide
Interferon alfa-n3 may lead to a major life threatening interaction when taken with Aldesleukin ... |
DB11757 | DB12141 | 960 | 971 | [
"DDInter994",
"DDInter817"
] | Istradefylline | Gilteritinib | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
960,
24,
971
]
],
[
[
960,
62,
1135
],
[
1135,
23,
971
]
],
[
[
960,
63,
1181
],
[
1181,
24,
971
]
],
[
[
960,
24,
283
],
[
283,
... | [
[
[
"Istradefylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Istradefylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
... | Istradefylline may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Istradefylline may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and T... |
DB00427 | DB01242 | 1,233 | 1,237 | [
"DDInter1879",
"DDInter410"
] | Triprolidine | Clomipramine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1233,
24,
1237
]
],
[
[
1233,
24,
684
],
[
684,
1,
1237
]
],
[
[
1233,
63,
902
],
[
902,
40,
1237
]
],
[
[
1233,
24,
272
],
[
272,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
],
... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Clomipramine (Co... |
DB01118 | DB11767 | 33 | 1,583 | [
"DDInter76",
"DDInter1643"
] | Amiodarone | Sarilumab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Sarilumab is a fully human anti-interleukin 6 (IL-6) receptor monoclonal IgG1 antibody that binds to both membrane-bound and soluble IL-6 receptor forms, thus blocking the cis- and trans-inflammatory signalling cascades of IL-6. Sarilumab was developed by Sanofi and Regeneron Pharmaceuticals, Inc; it was US FDA-approve... | Moderate | 1 | [
[
[
33,
24,
1583
]
],
[
[
33,
63,
267
],
[
267,
24,
1583
]
],
[
[
33,
24,
850
],
[
850,
24,
1583
]
],
[
[
33,
24,
738
],
[
738,
63,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarilumab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naltrexone"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Sarilumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin an... |
DB00802 | DB01181 | 1,322 | 1,532 | [
"DDInter43",
"DDInter906"
] | Alfentanil | Ifosfamide | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1322,
24,
1532
]
],
[
[
1322,
6,
7524
],
[
7524,
45,
1532
]
],
[
[
1322,
21,
28792
],
[
28792,
60,
1532
]
],
[
[
1322,
63,
1648
],
[
1... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",... | Alfentanil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Ifosfamide (Compound)
Alfentanil (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Ifosfamide (Compound)
Alfentanil may cause a moderate interaction that could exacerbate diseases whe... |
DB00911 | DB15093 | 458 | 1,654 | [
"DDInter1811",
"DDInter1698"
] | Tinidazole | Somapacitan | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
458,
24,
1654
]
],
[
[
458,
63,
168
],
[
168,
23,
1654
]
],
[
[
458,
63,
10
],
[
10,
24,
1654
]
],
[
[
458,
24,
351
],
[
351,
24... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone ma... |
DB00005 | DB00888 | 1,057 | 1,001 | [
"DDInter687",
"DDInter1133"
] | Etanercept | Mechlorethamine | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Major | 2 | [
[
[
1057,
25,
1001
]
],
[
[
1057,
25,
450
],
[
450,
1,
1001
]
],
[
[
1057,
24,
126
],
[
126,
23,
1001
]
],
[
[
1057,
25,
51
],
[
51,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mechlorethamine"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphami... | Etanercept may lead to a major life threatening interaction when taken with Cyclophosphamide and Cyclophosphamide (Compound) resembles Mechlorethamine (Compound)
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit ... |
DB00421 | DB11130 | 443 | 407 | [
"DDInter1707",
"DDInter1344"
] | Spironolactone | Opium | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
443,
24,
407
]
],
[
[
443,
24,
104
],
[
104,
24,
407
]
],
[
[
443,
63,
1648
],
[
1648,
24,
407
]
],
[
[
443,
25,
543
],
[
543,
2... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin an... |
DB00377 | DB01232 | 1,494 | 1,327 | [
"DDInter1382",
"DDInter1640"
] | Palonosetron | Saquinavir | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Major | 2 | [
[
[
1494,
25,
1327
]
],
[
[
1494,
24,
833
],
[
833,
1,
1327
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
1327
]
],
[
[
1494,
21,
28691
],
[
28691... | [
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
],
[
"Lopinav... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Lopinavir and Lopinavir (Compound) resembles Saquinavir (Compound)
Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Saquinavir (Compound)
Palonosetron (Compound) causes Somnolence (Side Effect) and Somn... |
DB01404 | DB04932 | 757 | 1,564 | [
"DDInter820",
"DDInter491"
] | Ginseng | Defibrotide | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Da... | Moderate | 1 | [
[
[
757,
24,
1564
]
],
[
[
757,
63,
1347
],
[
1347,
25,
1564
]
],
[
[
757,
24,
802
],
[
802,
64,
1564
]
],
[
[
757,
63,
1347
],
[
1347,
... | [
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Defibrotide"
]
],
[
[
"Ginseng",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
... | Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Defibrotide
Ginseng may cause a moderate interaction that could exacerbate diseases when taken with Tinzaparin and Tinzaparin may lead to a... |
DB00421 | DB00959 | 443 | 1,486 | [
"DDInter1707",
"DDInter1191"
] | Spironolactone | Methylprednisolone | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
443,
24,
1486
]
],
[
[
443,
1,
11347
],
[
11347,
40,
1486
]
],
[
[
443,
1,
1581
],
[
1581,
1,
1486
]
],
[
[
443,
24,
175
],
[
175,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Spironolactone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortamate"
],
[
"Hydrocortamate",
... | Spironolactone (Compound) resembles Hydrocortamate (Compound) and Hydrocortamate (Compound) resembles Methylprednisolone (Compound)
Spironolactone (Compound) resembles Testolactone (Compound) and Testolactone (Compound) resembles Methylprednisolone (Compound)
Spironolactone may cause a moderate interaction that could e... |
DB01059 | DB01234 | 956 | 1,220 | [
"DDInter1313",
"DDInter513"
] | Norfloxacin | Dexamethasone | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Major | 2 | [
[
[
956,
25,
1220
]
],
[
[
956,
64,
870
],
[
870,
1,
1220
]
],
[
[
956,
64,
175
],
[
175,
40,
1220
]
],
[
[
956,
6,
21998
],
[
21998,
... | [
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
]
],
[
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone... | Norfloxacin may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Norfloxacin may lead to a major life threatening interaction when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Norflo... |
DB00390 | DB08901 | 1,252 | 1,468 | [
"DDInter554",
"DDInter1492"
] | Digoxin | Ponatinib | Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the _Digi... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1252,
24,
1468
]
],
[
[
1252,
24,
478
],
[
478,
24,
1468
]
],
[
[
1252,
6,
10083
],
[
10083,
45,
1468
]
],
[
[
1252,
7,
5057
],
[
5057... | [
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nil... | Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Digoxin (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound)
Digoxin (Compound) upregulat... |
DB12010 | DB15328 | 214 | 829 | [
"DDInter785",
"DDInter1896"
] | Fostamatinib | Ubrogepant | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA. Recently, fosta... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
214,
24,
829
]
],
[
[
214,
24,
1476
],
[
1476,
24,
829
]
],
[
[
214,
63,
1468
],
[
1468,
24,
829
]
],
[
[
214,
64,
1510
],
[
1510,
... | [
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
... | Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Pon... |
DB01206 | DB11601 | 37 | 1,270 | [
"DDInter1086",
"DDInter1889"
] | Lomustine | Tuberculin purified protein derivative | An alkylating agent of value against both hematologic malignancies and solid tumors. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
37,
24,
1270
]
],
[
[
37,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
37,
63,
869
],
[
869,
24,
1270
]
],
[
[
37,
64,
1064
],
[
1064,
... | [
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Lomustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"C... | Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Lomustine may cause a moderate interaction that could exacerbate diseases when take... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.